carvedilol has been researched along with Gastrointestinal Hemorrhage in 50 studies
Gastrointestinal Hemorrhage: Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "136 patients with ACLF (with no or small esophageal varices and HVPG ≥ 12 mmHg) were randomized to either carvedilol (n = 66) or placebo arms (n = 70)." | 9.30 | Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial. ( Agarwal, PM; Bhardwaj, A; Choudhury, A; Jindal, A; Kainth, S; Kumar, G; Kumar, M; Maiwall, R; Mitra, LG; Saluja, V; Sarin, SK; Shasthry, SM, 2019) |
| "To assess the beneficial and harmful effects of carvedilol compared with traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices." | 8.98 | Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. ( Bendtsen, F; Gluud, LL; Hobolth, L; Jeyaraj, R; Morgan, MY; Zacharias, AP, 2018) |
| "In this prospective cohort study, 106 cirrhotic patients with high-risk esophageal varices in the derivation cohort received carvedilol prophylaxis, and completed paired measurements of hepatic venous pressure gradient, liver stiffness (LS), and spleen stiffness (SS) at the beginning and end of dose titration." | 7.91 | Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. ( Ahn, DW; Baik, SK; Jung, YJ; Kim, D; Kim, HY; Kim, MY; Kim, W; So, YH; Woo, H, 2019) |
| "Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis." | 6.82 | A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. ( Baik, SK; Jang, JY; Jeong, SW; Kim, DJ; Kim, MY; Kim, SG; Kim, TY; Kim, YS; Lee, B; Seo, YS; Sohn, JH; Suk, KT; Um, SH, 2016) |
| "Propranolol was used for secondary UVB prophylaxis in 43 (75." | 5.72 | Carvedilol as secondary prophylaxis for variceal bleeding in hepatosplenic schistosomiasis. ( Cançado, GGL; Cardoso, JB; Couto, CA; de Abreu, ES; Faria, LC; Ferrari, TCA; Lima, AMC; Nardelli, MJ; Osório, FMF, 2022) |
| " First-line therapies include carvedilol or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepatorenal syndrome." | 5.41 | Diagnosis and Management of Cirrhosis and Its Complications: A Review. ( Parikh, ND; Tapper, EB, 2023) |
| "Cirrhotic patients with esophageal varices and with baseline HVPG > 12 mm Hg were prospectively randomized for primary prophylaxis to receive either carvedilol (group A, n = 110) or carvedilol plus simvastatin (group B, n = 110)." | 5.34 | Hemodynamic Effects of Adding Simvastatin to Carvedilol for Primary Prophylaxis of Variceal Bleeding: A Randomized Controlled Trial. ( Arora, V; Choudhary, A; Jindal, A; Kumar, G; Sarin, SK; Vijayaraghavan, R, 2020) |
| "136 patients with ACLF (with no or small esophageal varices and HVPG ≥ 12 mmHg) were randomized to either carvedilol (n = 66) or placebo arms (n = 70)." | 5.30 | Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial. ( Agarwal, PM; Bhardwaj, A; Choudhury, A; Jindal, A; Kainth, S; Kumar, G; Kumar, M; Maiwall, R; Mitra, LG; Saluja, V; Sarin, SK; Shasthry, SM, 2019) |
| "Cirrhotic patients with esophageal varices were randomized to carvedilol 12." | 5.19 | Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial. ( Abid, S; Azam, Z; Hamid, S; Ismail, FW; Jafri, W; Khalid, A; Munir, SM; Parkash, O; Rauf, J; Shah, HA; Subhan, A, 2014) |
| "Patients with oesophageal varices undergoing measurement of HVPG before and under propranolol treatment (80-160 mg/day) were included." | 5.17 | Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. ( Ferlitsch, A; Heinisch, BB; Kramer, L; Payer, BA; Peck-Radosavljevic, M; Pinter, M; Reiberger, T; Schwabl, P; Trauner, M; Ulbrich, G, 2013) |
| "To assess the beneficial and harmful effects of carvedilol compared with traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices." | 4.98 | Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. ( Bendtsen, F; Gluud, LL; Hobolth, L; Jeyaraj, R; Morgan, MY; Zacharias, AP, 2018) |
| "The Beta-blockers Or Placebo for Primary Prophylaxis of oesophageal varices (BOPPP) trial is a 3-year phase IV, multi-centre clinical trial of investigational medicinal product (CTIMP) that aims to determine the effectiveness of carvedilol in the prevention of variceal bleeding for small oesophageal varices in patients with cirrhosis." | 4.12 | General practitioner perspectives on factors that influence implementation of secondary care-initiated treatment in primary care: Exploring implementation beyond the context of a clinical trial. ( Ahmed, H; Carter, B; Lawrence, V; Le Boutillier, C; McPhail, M; Patel, VC; Ward, C, 2022) |
| "In this prospective cohort study, 106 cirrhotic patients with high-risk esophageal varices in the derivation cohort received carvedilol prophylaxis, and completed paired measurements of hepatic venous pressure gradient, liver stiffness (LS), and spleen stiffness (SS) at the beginning and end of dose titration." | 3.91 | Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. ( Ahn, DW; Baik, SK; Jung, YJ; Kim, D; Kim, HY; Kim, MY; Kim, W; So, YH; Woo, H, 2019) |
| "220 patients with known esophageal varices on upper GI endoscopy and no previous history of GI bleed were randomized to group A (Carvedilol) and group B (Propranolol)." | 3.30 | Comparison of carvedilol and propranolol for primary prophylaxis of esophageal variceal bleed in cirrhotic patients. ( Aneeza Ilyas, -; Khalid Mahmud Khan, -; Maria, -; Muhammad Adnan Iqbal, -; Muhammad Farooq Hanif, -; Nooman Gilani, -; Raja Omer Fiaz, -, 2023) |
| "Portal hypertension is the primary driver of decompensation, including the development of ascites, hepatic encephalopathy and variceal haemorrhage." | 3.01 | Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis. ( Gillespie, SL; Hanrahan, TP; Hayes, PC; Majumdar, A; Rockey, DC, 2023) |
| "Carvedilol is a non-selective beta-blocker (NSBB) acting on hyperdynamic circulation/splanchnic vasodilation and on intrahepatic resistance." | 3.01 | Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. ( La Mura, V; Reiberger, T; Turco, L; Vitale, G, 2023) |
| " Carvedilol-specific experience was also influenced by the manifestation of side effects and patient dosage routine." | 3.01 | Exploring patients' perceptions and experiences of treatments for the prevention of variceal bleeding: a qualitative study. ( Mathers, J; Poyner, C; Tripathi, D, 2021) |
| "Carvedilol is a rising nonselective beta-blocker used for reducing portal pressure with favorable outcome." | 2.87 | Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding. ( Abd ElRahim, AY; Elsharkawy, A; Fathalah, W; Fouad, R; Khairy, M; Khatamish, H; Khorshid, O; Moussa, M; Seyam, M, 2018) |
| "Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis." | 2.82 | A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. ( Baik, SK; Jang, JY; Jeong, SW; Kim, DJ; Kim, MY; Kim, SG; Kim, TY; Kim, YS; Lee, B; Seo, YS; Sohn, JH; Suk, KT; Um, SH, 2016) |
| "Carvedilol is a vasodilating non-selective β-blocker with alpha-1 receptor and calcium channel antagonism." | 2.79 | Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding. ( Dickson, S; Forrest, EH; Gaya, DR; Hayes, PC; Leithead, JA; MacBeth, K; Mills, PR; Smith, L; Stanley, AJ; Suzuki, H; Tripathi, D; Young, D, 2014) |
| "Recurrent bleeding from esophageal varices occurred in 31 patients (51%) in the carvedilol group and in 26 patients (43%) in the N + I group (P = 0." | 2.77 | Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. ( Chen, WC; Lo, GH; Wang, HM; Yu, HC, 2012) |
| "Carvedilol is an option for primary prophylaxis in patients with high-risk esophageal varices." | 2.74 | Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. ( Ferguson, JW; Forrest, EH; Hayes, PC; Hislop, WS; Kochar, N; Leithead, JA; McAvoy, NC; Mills, PR; Stanley, AJ; Therapondos, G; Tripathi, D, 2009) |
| "Recent advances in the pharmacologic treatment of portal hypertension have mainly focused on modifying an increased intrahepatic resistance through nitric oxide and/or modulation of vasoactive substances." | 2.61 | Pharmacologic Management of Portal Hypertension. ( Bunchorntavakul, C; Reddy, KR, 2019) |
| "Carvedilol was more efficacious than traditional NSBBs in decreasing the variceal rebleeding rate [odds ratio (OR): 0." | 2.61 | The efficacy comparison of carvedilol plus endoscopic variceal ligation and traditional, nonselective β-blockers plus endoscopic variceal ligation in cirrhosis patients for the prevention of variceal rebleeding: a meta-analysis. ( Chen, L; Ge, K; Yang, J; Yang, JL, 2019) |
| "Frequently, relevant liver fibrosis is diagnosed by non-invasive methods (e." | 2.58 | [Management of compensated liver cirrhosis 2018 - Evidence based prophylactic measures]. ( Benten, D; Karkmann, K; Kluwe, J; Piecha, F; Rünzi, AC; Schulz, L; von Wulffen, M; Wege, H, 2018) |
| "Once gastroesophageal varices have developed, non-selective beta-blockers remain the cornerstone of therapy." | 2.55 | Prevention and treatment of variceal haemorrhage in 2017. ( Berzigotti, A; Bosch, J; Brunner, F, 2017) |
| "Propranolol was used for secondary UVB prophylaxis in 43 (75." | 1.72 | Carvedilol as secondary prophylaxis for variceal bleeding in hepatosplenic schistosomiasis. ( Cançado, GGL; Cardoso, JB; Couto, CA; de Abreu, ES; Faria, LC; Ferrari, TCA; Lima, AMC; Nardelli, MJ; Osório, FMF, 2022) |
| "Carvedilol was shown to have a positive effect on gastric varices without significant adverse effects." | 1.56 | CARVEDILOL AS PRIMARY PROPHYLAXIS FOR GASTRIC VARICEAL BLEEDING IN PORTAL HYPERTENSION MODEL IN RATS. ( Bertoldi, AS; Brighenti, LMV; Coltro, GA; Fauat, NI; Guetter, CR; Kubrusly, FB; Kubrusly, LF; Marques, CAM; Vosgerau, LM, 2020) |
| "Carvedilol 12." | 1.48 | Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. ( Ferlitsch, A; Kivaranovic, D; Mandorfer, M; Paternostro, R; Peck-Radosavljevic, M; Reiberger, T; Schwarzer, R; Trauner, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (4.00) | 29.6817 |
| 2010's | 30 (60.00) | 24.3611 |
| 2020's | 18 (36.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Abreu, ES | 1 |
| Nardelli, MJ | 1 |
| Lima, AMC | 1 |
| Cardoso, JB | 1 |
| Osório, FMF | 1 |
| Ferrari, TCA | 1 |
| Faria, LC | 1 |
| Couto, CA | 1 |
| Cançado, GGL | 1 |
| Dunne, PDJ | 1 |
| Young, D | 2 |
| Chuah, CS | 2 |
| Hayes, PC | 5 |
| Tripathi, D | 7 |
| Leithead, J | 1 |
| Smith, LA | 1 |
| Gaya, DR | 2 |
| Forrest, E | 1 |
| Stanley, AJ | 5 |
| Jachs, M | 1 |
| Hartl, L | 1 |
| Simbrunner, B | 1 |
| Bauer, D | 1 |
| Paternostro, R | 2 |
| Balcar, L | 1 |
| Hofer, B | 1 |
| Pfisterer, N | 1 |
| Schwarz, M | 1 |
| Scheiner, B | 1 |
| Stättermayer, AF | 1 |
| Pinter, M | 3 |
| Trauner, M | 4 |
| Mandorfer, M | 4 |
| Reiberger, T | 7 |
| Bosch, J | 6 |
| Gralnek, IM | 1 |
| Camus Duboc, M | 1 |
| Garcia-Pagan, JC | 2 |
| Fuccio, L | 1 |
| Karstensen, JG | 1 |
| Hucl, T | 1 |
| Jovanovic, I | 1 |
| Awadie, H | 1 |
| Hernandez-Gea, V | 2 |
| Tantau, M | 1 |
| Ebigbo, A | 1 |
| Ibrahim, M | 1 |
| Vlachogiannakos, J | 1 |
| Burgmans, MC | 1 |
| Rosasco, R | 1 |
| Triantafyllou, K | 1 |
| Le Boutillier, C | 1 |
| Ahmed, H | 1 |
| Patel, VC | 2 |
| McPhail, M | 1 |
| Carter, B | 2 |
| Ward, C | 1 |
| Lawrence, V | 1 |
| McPhail, MJW | 1 |
| Gillespie, SL | 1 |
| Hanrahan, TP | 1 |
| Rockey, DC | 1 |
| Majumdar, A | 1 |
| Villanueva, C | 2 |
| Torres, F | 2 |
| Turco, L | 1 |
| Vitale, G | 1 |
| La Mura, V | 1 |
| Tapper, EB | 1 |
| Parikh, ND | 1 |
| Muhammad Farooq Hanif, - | 1 |
| Raja Omer Fiaz, - | 1 |
| Muhammad Adnan Iqbal, - | 1 |
| Aneeza Ilyas, - | 1 |
| Maria, - | 1 |
| Khalid Mahmud Khan, - | 1 |
| Nooman Gilani, - | 1 |
| Kumar, M | 1 |
| Kainth, S | 1 |
| Choudhury, A | 1 |
| Maiwall, R | 1 |
| Mitra, LG | 1 |
| Saluja, V | 1 |
| Agarwal, PM | 1 |
| Shasthry, SM | 1 |
| Jindal, A | 2 |
| Bhardwaj, A | 1 |
| Kumar, G | 2 |
| Sarin, SK | 2 |
| Bunchorntavakul, C | 1 |
| Reddy, KR | 1 |
| El Shahawy, MS | 1 |
| Shady, ZM | 1 |
| Gaafar, A | 1 |
| Huang, X | 1 |
| Fan, X | 1 |
| Chen, S | 1 |
| Chen, WC | 3 |
| Hou, MC | 2 |
| Vijayaraghavan, R | 1 |
| Arora, V | 1 |
| Choudhary, A | 1 |
| McDowell, HR | 1 |
| Forrest, EH | 3 |
| Bertoldi, AS | 1 |
| Guetter, CR | 1 |
| Coltro, GA | 1 |
| Vosgerau, LM | 1 |
| Brighenti, LMV | 1 |
| Fauat, NI | 1 |
| Kubrusly, FB | 1 |
| Marques, CAM | 1 |
| Kubrusly, LF | 1 |
| Poyner, C | 1 |
| Mathers, J | 1 |
| Püspök, A | 1 |
| Schoder, M | 1 |
| Baumann-Durchschein, F | 1 |
| Bucsics, T | 1 |
| Datz, C | 1 |
| Dolak, W | 1 |
| Ferlitsch, A | 4 |
| Finkenstedt, A | 1 |
| Graziadei, I | 1 |
| Hametner, S | 1 |
| Karnel, F | 1 |
| Krones, E | 1 |
| Maieron, A | 1 |
| Peck-Radosavljevic, M | 4 |
| Rainer, F | 1 |
| Schwabl, P | 2 |
| Stadlbauer, V | 1 |
| Stauber, R | 1 |
| Tilg, H | 1 |
| Zoller, H | 1 |
| Schöfl, R | 1 |
| Fickert, P | 1 |
| Abd ElRahim, AY | 1 |
| Fouad, R | 1 |
| Khairy, M | 1 |
| Elsharkawy, A | 1 |
| Fathalah, W | 1 |
| Khatamish, H | 1 |
| Khorshid, O | 1 |
| Moussa, M | 1 |
| Seyam, M | 1 |
| Baiges, A | 1 |
| Karkmann, K | 1 |
| Piecha, F | 1 |
| Rünzi, AC | 1 |
| Schulz, L | 1 |
| von Wulffen, M | 1 |
| Benten, D | 1 |
| Kluwe, J | 1 |
| Wege, H | 1 |
| Robertson, M | 1 |
| Hayes, P | 1 |
| Schwarzer, R | 1 |
| Kivaranovic, D | 1 |
| Zacharias, AP | 1 |
| Jeyaraj, R | 1 |
| Hobolth, L | 1 |
| Bendtsen, F | 1 |
| Gluud, LL | 1 |
| Morgan, MY | 1 |
| Kim, HY | 1 |
| So, YH | 1 |
| Kim, W | 1 |
| Ahn, DW | 1 |
| Jung, YJ | 1 |
| Woo, H | 1 |
| Kim, D | 1 |
| Kim, MY | 2 |
| Baik, SK | 2 |
| Hsin, IF | 1 |
| Chen, PH | 1 |
| Hsu, PI | 1 |
| Wang, YP | 1 |
| Cheng, JS | 1 |
| Lin, HS | 1 |
| Lee, FY | 1 |
| Albillos, A | 1 |
| Genescà, J | 1 |
| Calleja, JL | 1 |
| Aracil, C | 1 |
| Bañares, R | 1 |
| Morillas, RM | 1 |
| Poca, M | 1 |
| Peñas, B | 1 |
| Augustin, S | 1 |
| Abraldes, JG | 1 |
| Alvarado, E | 1 |
| Yang, J | 1 |
| Ge, K | 1 |
| Chen, L | 1 |
| Yang, JL | 1 |
| Shah, HA | 1 |
| Azam, Z | 1 |
| Rauf, J | 1 |
| Abid, S | 1 |
| Hamid, S | 1 |
| Jafri, W | 1 |
| Khalid, A | 1 |
| Ismail, FW | 1 |
| Parkash, O | 1 |
| Subhan, A | 1 |
| Munir, SM | 1 |
| Simonetto, DA | 1 |
| Shah, VH | 1 |
| Kamath, PS | 1 |
| Dickson, S | 1 |
| Mills, PR | 2 |
| Leithead, JA | 2 |
| MacBeth, K | 1 |
| Smith, L | 1 |
| Suzuki, H | 1 |
| Li, T | 1 |
| Ke, W | 1 |
| Sun, P | 1 |
| Chen, X | 1 |
| Belgaumkar, A | 1 |
| Huang, Y | 1 |
| Xian, W | 1 |
| Li, J | 1 |
| Zheng, Q | 1 |
| Kim, SG | 1 |
| Kim, TY | 1 |
| Sohn, JH | 1 |
| Um, SH | 1 |
| Seo, YS | 1 |
| Jang, JY | 1 |
| Jeong, SW | 1 |
| Lee, B | 1 |
| Kim, YS | 1 |
| Suk, KT | 1 |
| Kim, DJ | 1 |
| Gupta, V | 1 |
| Rawat, R | 1 |
| Saraya, A | 1 |
| Brunner, F | 1 |
| Berzigotti, A | 1 |
| Steib, CJ | 1 |
| Gerbes, AL | 1 |
| Ferguson, JW | 1 |
| Kochar, N | 1 |
| Therapondos, G | 1 |
| McAvoy, NC | 1 |
| Hislop, WS | 1 |
| Tsochatzis, EA | 1 |
| Triantos, CK | 1 |
| Burroughs, AK | 1 |
| Wang, CC | 1 |
| Kao, JH | 1 |
| Payer, BA | 2 |
| Homoncik, M | 1 |
| Lo, GH | 1 |
| Wang, HM | 1 |
| Yu, HC | 1 |
| Ulbrich, G | 1 |
| Heinisch, BB | 1 |
| Kramer, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Nonselective Beta Blockers vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices[NCT02583698] | 136 participants (Actual) | Interventional | 2015-10-01 | Completed | |||
| A Prospective Randomized Study to Compare the Efficacy and Safety of Carvedilol With or Without Simvastatin in Patients With Portal Hypertension and Esophageal Varices[NCT02465645] | 220 participants (Actual) | Interventional | 2015-06-01 | Completed | |||
| A Prospective Multicenter Cohort Study on the Timing of Emergency Endoscopy for Esophagogastric Variceal Bleeding in Cirrhosis[NCT04932200] | 608 participants (Anticipated) | Observational | 2021-06-15 | Not yet recruiting | |||
| Timing of Endoscopic Intervention in Patients With Cirrhosis With Acute Variceal Upper Gastrointestinal Hemorrhage (TEACH Trial): a Randomized Clinical Trial[NCT04786743] | 400 participants (Anticipated) | Interventional | 2021-04-20 | Recruiting | |||
| Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis: a Prospective Cohort Study[NCT04543643] | Phase 3 | 288 participants (Anticipated) | Interventional | 2021-11-01 | Not yet recruiting | ||
| Prospective Cohort Study to Evaluate Long-term Outcomes in Patients With Liver Cirrhosis of Boramae Hospital[NCT01943318] | 500 participants (Actual) | Observational [Patient Registry] | 2013-01-31 | Completed | |||
| Spleen Stiffness Combined With Liver Stiffness Measured by Two-dimensional Shear Wave Elastography for the Screening of High-risk Varices in Patients With Compensated Advanced Chronic Liver Disease (CHESS2004)[NCT04546360] | 300 participants (Anticipated) | Observational [Patient Registry] | 2020-09-08 | Recruiting | |||
| Carvedilol Plus Endoscopic Cyanoacrylate Injection Versus Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding[NCT02504723] | Phase 4 | 121 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| A Novel Algorithm to Stratify Clinical Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108)[NCT05100485] | 1,000 participants (Actual) | Observational | 2022-01-01 | Completed | |||
| Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension[NCT01059396] | Phase 4 | 201 participants (Actual) | Interventional | 2010-01-28 | Completed | ||
| CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease: an International Multicenter Study (CHESS2102)[NCT04975477] | 1,000 participants (Anticipated) | Observational | 2021-07-16 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
All adverse effects during the study period (NCT02504723)
Timeframe: Within 6 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cyanoacrylate Injection Plus Carvedilol | 32 |
| Cyanoacrylate Injection | 9 |
All cause mortality or liver transplantation during the study period (NCT02504723)
Timeframe: Within 6 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cyanoacrylate Injection Plus Carvedilol | 13 |
| Cyanoacrylate Injection | 20 |
All upper gastrointestinal bleeding during the follow-up period (NCT02504723)
Timeframe: Within 6 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cyanoacrylate Injection Plus Carvedilol | 17 |
| Cyanoacrylate Injection | 29 |
Rebleeding from gastric varices during the follow-up period (NCT02504723)
Timeframe: Within 6 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cyanoacrylate Injection Plus Carvedilol | 14 |
| Cyanoacrylate Injection | 21 |
14 reviews available for carvedilol and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
Carvedilol in patients with compensated cirrhosis: The ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Lo | 2023 |
Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis.
Topics: Adrenergic beta-Antagonists; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal H | 2023 |
Reply to: "Carvedilol in patients with compensated cirrhosis: The ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices".
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Lo | 2023 |
Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.
Topics: Adrenergic beta-Antagonists; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal H | 2023 |
Diagnosis and Management of Cirrhosis and Its Complications: A Review.
Topics: Adult; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatic Enc | 2023 |
Pharmacologic Management of Portal Hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Anticoagulants; Antihypertensi | 2019 |
Pharmacologic prevention of variceal bleeding and rebleeding.
Topics: Adrenergic beta-Antagonists; Atorvastatin; Carbazoles; Carvedilol; Esophageal and Gastric Varices; G | 2018 |
[Management of compensated liver cirrhosis 2018 - Evidence based prophylactic measures].
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Germany; Hepatic Encephalop | 2018 |
Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices.
Topics: Adrenergic beta-Antagonists; Adult; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hem | 2018 |
The efficacy comparison of carvedilol plus endoscopic variceal ligation and traditional, nonselective β-blockers plus endoscopic variceal ligation in cirrhosis patients for the prevention of variceal rebleeding: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Carvedilol; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices | 2019 |
Primary prophylaxis of variceal bleeding.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Esopha | 2014 |
Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Esophageal and Ga | 2016 |
Beta blockers and cirrhosis, 2016.
Topics: Acute Kidney Injury; Adrenergic beta-Antagonists; Ascites; Carbazoles; Carvedilol; Esophageal and Ga | 2017 |
Prevention and treatment of variceal haemorrhage in 2017.
Topics: Adrenergic beta-Antagonists; Anti-Bacterial Agents; Balloon Occlusion; Carbazoles; Carvedilol; Endos | 2017 |
16 trials available for carvedilol and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
Carvedilol versus endoscopic band ligation for secondary prophylaxis of variceal bleeding-long-term follow-up of a randomised control trial.
Topics: Carvedilol; Esophageal and Gastric Varices; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; | 2022 |
Comparison of carvedilol and propranolol for primary prophylaxis of esophageal variceal bleed in cirrhotic patients.
Topics: Adrenergic beta-Antagonists; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage | 2023 |
Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial.
Topics: Acute-On-Chronic Liver Failure; Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Carv | 2019 |
Hemodynamic Effects of Adding Simvastatin to Carvedilol for Primary Prophylaxis of Variceal Bleeding: A Randomized Controlled Trial.
Topics: Adrenergic beta-Antagonists; Adult; Carvedilol; Drug Therapy, Combination; Esophageal and Gastric Va | 2020 |
Carvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up study.
Topics: Adrenergic beta-Antagonists; Carvedilol; Esophageal and Gastric Varices; Follow-Up Studies; Gastroin | 2021 |
Exploring patients' perceptions and experiences of treatments for the prevention of variceal bleeding: a qualitative study.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Ligation; Perceptio | 2021 |
Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Egypt; Esophageal and Gastric Vari | 2018 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; | 2014 |
Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Carvedilol; Esophageal and Gastric V | 2014 |
A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis.
Topics: Adult; Antihypertensive Agents; Ascites; Carbazoles; Carvedilol; End Stage Liver Disease; Esophageal | 2016 |
Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed: RCT.
Topics: Adult; Antihypertensive Agents; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Esophagoscop | 2017 |
Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Fe | 2009 |
Gastrointestinal bleeding: Carvedilol-the best beta-blocker for primary prophylaxis?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Endoscopy; Esophageal and Gastric Varices; Gast | 2009 |
Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Chi-Square Distribution; Dru | 2012 |
Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; | 2013 |
20 other studies available for carvedilol and Gastrointestinal Hemorrhage
| Article | Year |
|---|---|
Carvedilol as secondary prophylaxis for variceal bleeding in hepatosplenic schistosomiasis.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Ligation; Propranol | 2022 |
Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis.
Topics: Adrenergic beta-Antagonists; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage | 2023 |
Carvedilol as Best β-Blocker for Secondary Prophylaxis of Variceal Bleeding: Are We There, or Not Yet?
Topics: Adrenergic beta-Antagonists; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage | 2023 |
Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.
Topics: Carvedilol; Cyanoacrylates; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Gastrointes | 2022 |
General practitioner perspectives on factors that influence implementation of secondary care-initiated treatment in primary care: Exploring implementation beyond the context of a clinical trial.
Topics: Adrenergic beta-Antagonists; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage | 2022 |
The Efficacy of Argon Plasma Coagulation versus Carvedilol for Treatment of Portal Hypertensive Gastropathy.
Topics: Argon Plasma Coagulation; Carvedilol; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Sto | 2020 |
Individualized Treatment of Gastric Varices in Cirrhotic Portal Hypertension.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Porta | 2019 |
Reply.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Re | 2019 |
KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.
Topics: Adrenergic beta-Antagonists; Ammonia; Anti-Bacterial Agents; Carvedilol; Disaccharides; Endoscopy, G | 2020 |
CARVEDILOL AS PRIMARY PROPHYLAXIS FOR GASTRIC VARICEAL BLEEDING IN PORTAL HYPERTENSION MODEL IN RATS.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Carvedilol; Esophageal and Gastric Va | 2020 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Primary prophylaxis of variceal bleeding.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Endoscopy; Esophageal and Gastric Varices; Gast | 2018 |
Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study.
Topics: Antihypertensive Agents; Carvedilol; Dose-Response Relationship, Drug; Esophageal and Gastric Varice | 2018 |
Editorial: optimal dose of carvedilol in portal hypertension…nearly there.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Porta | 2018 |
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
Topics: Adrenergic beta-Antagonists; Carvedilol; Chemoprevention; Clinical Decision Rules; Elasticity Imagin | 2019 |
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
Topics: Adrenergic beta-Antagonists; Carvedilol; Chemoprevention; Clinical Decision Rules; Elasticity Imagin | 2019 |
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
Topics: Adrenergic beta-Antagonists; Carvedilol; Chemoprevention; Clinical Decision Rules; Elasticity Imagin | 2019 |
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
Topics: Adrenergic beta-Antagonists; Carvedilol; Chemoprevention; Clinical Decision Rules; Elasticity Imagin | 2019 |
Addition of Carvedilol to Gastric Variceal Obturation Does Not Decrease Recurrence of Gastric Variceal Bleeding in Patients With Cirrhosis.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carvedilol; Endoscopy, Gastrointestinal | 2019 |
Secondary prophylaxis for variceal bleeding: carvedilol vs. propranolol.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Drug Monitoring; Esophageal and | 2017 |
Carvedilol versus variceal band ligation for prevention of the first variceal bleed.
Topics: Carbazoles; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hyperte | 2010 |
Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Elasticity; Elasticity Imaging Technique | 2012 |
Carvedilol: the β-blocker of choice for portal hypertension?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Female; Gastroi | 2013 |